These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7913659)

  • 1. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents.
    Gotteland M; May E; May-Levin F; Contesso G; Delarue JC; Mouriesse H
    Cancer; 1994 Aug; 74(3):864-71. PubMed ID: 7913659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.
    Pawlowski V; Révillion F; Hebbar M; Hornez L; Peyrat JP
    Clin Cancer Res; 2000 Nov; 6(11):4217-25. PubMed ID: 11106235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression.
    May E; Mouriesse H; May-Levin F; Qian JF; May P; Delarue JC
    Br J Cancer; 1990 Sep; 62(3):430-5. PubMed ID: 1976381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients.
    Elledge RM; Ciocca DR; Langone G; McGuire WL
    Cancer; 1993 Apr; 71(8):2499-506. PubMed ID: 8095853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-alpha mRNA in primary breast cancer: relationship to estrogen and progesterone receptor proteins and other prognostic factors.
    Chearskul S; Bhothisuwan K; Churintrapun M; Semprasert N; Onreabroi S
    Asian Pac J Allergy Immunol; 2002 Mar; 20(1):13-21. PubMed ID: 12125913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.
    Watanabe T; Fukutomi T; Tsuda H; Adachi I; Nanasawa T; Yamamoto H; Abe K
    Jpn J Cancer Res; 1993 Dec; 84(12):1279-86. PubMed ID: 7904987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
    Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
    Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.
    Iwase H; Kobayashi S; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Naito A; Yamashita T; Itoh K; Masaoka A
    Breast Cancer Res Treat; 1993 Dec; 28(3):215-21. PubMed ID: 7912560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.
    Schönborn I; Zschiesche W; Spitzer E; Minguillon C; Möhner M; Ebeling K; Grosse R
    Breast Cancer Res Treat; 1994; 29(3):287-95. PubMed ID: 7914107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.
    Foekens JA; Portengen H; van Putten WL; Peters HA; Krijnen HL; Alexieva-Figusch J; Klijn JG
    Cancer Res; 1989 Nov; 49(21):5823-8. PubMed ID: 2676151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma.
    Tauchi K; Hori S; Itoh H; Osamura RY; Tokuda Y; Tajima T
    Virchows Arch A Pathol Anat Histopathol; 1989; 416(1):65-73. PubMed ID: 2573192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features.
    Rocha RL; Hilsenbeck SG; Jackson JG; Lee AV; Figueroa JA; Yee D
    J Natl Cancer Inst; 1996 May; 88(9):601-6. PubMed ID: 8609661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.